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Abstract
During the past years in vivo transplantation experiments and in vitro colony-forming assays indicated that tumors arise 
only from rare cells. These cells were shown to bear self-renewal capacities and the ability to recapitulate all cell types 
within an individual tumor. Due to their phenotypic resemblance to normal stem cells, the term "cancer stem cells" is 
used. However, some pieces of the puzzle are missing: (a) a stringent definition of cancer stem cells in solid tumors (b) 
specific markers that only target cells that meet the criteria for a cancer stem cell in a certain type of tumor. These 
missing parts started an ongoing debate about which is the best method to identify and characterize cancer stem 
cells, or even if their mere existence is just an artifact caused by the experimental procedures. Recent findings query 
the cancer stem cell hypothesis for solid tumors itself since it was shown in xenograft transplantation experiments that 
under appropriate conditions tumor-initiating cells are not rare.
In this review we critically discuss the challenges and prospects of the currently used major methods to identify cancer 
stem cells. Further on, we reflect the present discussion about the existence of cancer stem cells in solid tumors as well 
as the amount and characteristics of tumor-initiating cells and finally provide new perspectives like the correlation of 
cancer stem cells and induced pluripotent cells.
Review
Introduction
Already 150 years ago, the German pathologist Rudolf
Virchow postulated in his theory of the cellular pathology
that cancer initiates from immature cells [1]. But it still
took 100 years until Sajiro Makino introduced the term
"tumor stem cell" for a small subpopulation of cells that
were insensitive to chemotherapy and had chromosomal
features different from the bulk of cells [2]. In the 1970s in
vivo  transplantation experiments and in vitro colony-
forming assays supported Makino's observation that
tumors could arise from rare cells with self-renewal
capacities. Experiments indicated that these cells are able
to recapitulate all cell types within an individual tumor
and establish immortal cell lines [3-5].
These so called cancer stem cells (CSC) have been pro-
posed to originate either from malignant transformation
of a normal somatic stem cell or a progenitor cell [6] (Fig-
ure 1). Since stem cells proliferate throughout life they are
more susceptible to accumulate oncogenic mutations
than differentiated cells with their comparatively short
life span [7,8].
On the other hand, it could be that differentiated cells
reacquire stem cell-like characteristics by the reactivation
of signaling pathways like the Wnt-beta-catenin and
Bmi1 pathway or certain Hox genes that facilitate self-
renewal and are linked to malignant transformation of
cells [9-11].
One of the great advantages of the cancer stem cell
hypothesis is that it also helps understanding other can-
cer concepts such as cancer as a minimal residual disease.
Even a single cell that evades the surgeon's blade or adju-
vant therapies by acquired resistance like effective DNA
repair mechanisms or high amounts of active ABC trans-
porters that rapidly efflux chemotherapeutics recapitu-
lates the whole tumorigenesis resulting in a relapse after
what seems like a successful cancer treatment.
If the cancer stem cell hypothesis holds true at least for
some tumor entities, this calls for new pharmacological
perspectives to efficiently target these cells to prevent
relapse and metastasis. While specific cell surface mark-
ers for CSCs in hematological malignancies are widely
accepted and the concept of only a rare subpopulation of
cancer cells that exhibit stem cell-like characteristics and
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promote growth of hematological tumors is far beyond
any doubt, the situation looks totally different in solid
tumors. Whereas some scientists still argue about the
best method to identify and characterize CSCs, others
already query the CSC hypothesis in solid tumors itself
since it was shown in xenograft transplantation models
that under appropriate conditions tumor-initiating cells
are not rare [12]. Much of the confusion in the field
comes from the varying definitions of cancer stem cells.
For example, asymmetric cell division vs. self-renewal:
any cell that divides to give two daughter cells identical to
the parental cells has self-renewed, and presumably the
majority of cells within a tumor that are dividing self-
renew in this sense. Thus, there must be more to a defini-
tion of a cancer stem cell than self-renewal. The key is
whether a cell can yield multiple different sub-popula-
tions cells within a tumor that found a hierarchy within
the tumor by asymmetric cell division.
In this review we discuss the prospects and challenges
of the currently used main methods to identify CSCs.
Further on, we reflect the present discussion about the
existence of CSCs as well as the amount and characteris-
tics of tumor-initiating cells and finally provide new per-
spectives like the correlation of CSCs and induced
pluripotent cells.
Current standards of identification
The identification of a putative cancer stem cell subpopu-
lation with validated methods and markers for each
tumor entity remains controversial. So far, researchers
take advantage of known stem cell characteristics like the
ability to self-renew, expression of stem cell markers and
their multipotency. The most widely accepted assays to
validate a candidate cancer stem cell subpopulation are
efflux analysis of the DNA-binding dye Hoechst as well as
detection of known stem cell markers in cancer cells and
verification by xenotransplantations.
Cell surface markers
In the last decade several molecular properties have been
utilized to identify and characterize CSCs from different
hematopoietic and solid tumors. The first markers used
were cell surface proteins already known to define stem
and progenitor cells, e.g. CD133 and CD166. Further-
more, molecules that facilitate drug resistance in cancer
cells like ABCB1 and ABCG2 were added to the list of
putative CSC markers as well as proteins for which no
involvement in stemness or cancerogenesis was known,
e.g. CD20. In the following section we discuss examples
of proposed markers which were mostly used to identify
CSCs of solid tumors in the past.
CD133 (also known as Prominin 1), a member of pen-
taspan transmembrane glycoproteins, is expressed in
hematopoietic stem cells, endothelial progenitor cells,
neuronal and glial stem cells [13-15] and specifically
localizes to cellular protrusions [16]. CD133 has previ-
ously also been shown to be expressed in subpopulations
of cancer cells from brain, colon, lung, melanoma and
other solid tumors. This led to the assumption that
CD133 expressing tumor cells have stem cell or progeni-
tor like properties and CD133 was proposed as CSC
marker [7,17-19].
To illustrate the correlation of CD133 expression with
the level of differentiation of a certain cell type, the group
of Huttner generated an antibody that recognizes CD133
independently of potential posttranslational modifica-
tions as glycosylation. They found that the expression of
CD133 is independent from the cell's state of differentia-
tion, while posttranslational glycosylation negatively cor-
relates with differentiation [20]. Only AC133, the
glycosylated epitope of CD133, is downregulated upon
cell differentiation. Therefore it seems likely that upon
dedifferentiation of cells as observed in oncogenesis the
glycosylation of CD133 (AC133) might also increase and
serve as a marker for the tumorigenic potential of a cell.
K e e p i n g  t h i s  i n  m i n d ,  o n e  h a s  t o  b e  c a u t i o u s  w h e n
interpreting results from experiments where it is unclear
if the antibody detected CD133 or AC133 as many groups
in the field seem to use the term CD133 synonymously to
AC133. This inattentiveness could lead to confusions in
interpreting the results.
In 2007 Klein et al. have observed an increased expres-
sion of CD133 in primary and metastatic melanoma com-
pared to melanocytic nevi [21]. Subsequently, other
g r o u p s  f o u n d  t h a t  a l s o  i n  a  v a r i e t y  o f  t u m o r s  s u c h  a s
hepatocellular and rectal cancer an increased CD133
expression corresponds with higher stage tumors and
poor prognosis [22,23].
Figure 1 Origin of Cancer stem cells. In normal tissue, stem cells 
(green) divide asymmetrically into progenitor cells (orange) from 
which then terminally differentiated cells (red) are produced (left). In 
tumorigenesis mutations can transform stem cells into cancer stem 
cells (light blue) which then result in tumorigenic progenitor cells and 
differentiated tumor cells (dark blue). But also, by mutations in devel-
opmental pathways progenitor cells and differentiated cells can re-ac-
quire stem cell-like properties and turn into cancer stem cells (right).Welte et al. Cell Communication and Signaling 2010, 8:6
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Previously, disseminated tumor cells of melanoma
patients with metastatic disease have been shown to
express stem cell markers CD133 and NESTIN [24].
Those disseminated tumor cells are currently under
debate of being involved in the formation of metastases
and correlation with poor prognosis [25]. However,
beyond any doubts is the anchorage-independent growth
of these disseminated tumor cells which is also a charac-
teristic of stem cells from various types of self-renewing
tissue [26,27].
In cell culture experiments, antibody reactivity against
CD133 has been shown to correlate with the cell cycle
DNA profile of colon cancer, melanoma, and human
embryonic stem cells. Cells with highest ectopic expres-
sion of CD133 had a DNA content of 4N or even greater
and reflect cycling cells [28]. These findings are concor-
dant with the results of Grskovic and Liu that CD133+
cells have a higher mitotic index compared to CD133-
cells in the first week of cultivation [29,30].
Moreover, Liu et al. showed that CD133 expression is
significantly higher in recurrent glioblastoma tissue as
compared to their respective primary tumors. Addition-
ally, CD133+ cells in three primary cultured cell lines
established from glioblastoma patients showed an
increased expression of proteins associated with neural
precursors, e.g. CD90, NESTIN and MSI1 compared to
autologous CD133-  cells as well as higher levels of
ABCG2 and the DNA repair protein MGMT and higher
mRNA levels of anti-apoptotic genes. For the first time
ever, this study provided evidence that these properties
contribute to the tumor's resistance to chemotherapy.
CD133+ CSCs were significantly more resistant to che-
motherapeutic agents compared to autologous CD133-
cells [30].
CD133+ cells within human osteosarcoma cell lines as
well as human melanomas were also shown to have many
CSC like properties as for example formation of sphere-
like colonies after cultivation under serum-free condi-
tions [7,31].
Finally, CD133+ cells of various tumor entities were
shown to have an increased tumorigenic potential. For
melanoma this was demonstrated for the first time by
Monzani and collegues. Magnetically sorted CD133+ and
CD133- cells respectively, were injected into NOD-SCID
mice. After 40-50 days, mice injected with CD133+ cells
developed detectable tumors, whereas mice injected with
CD133- melanoma cells did not develop neoplasia even 4
months after injection [7].
In addition to its role as a cancer stem cell marker,
CD133 could also serve as an important therapeutic tar-
get for metastatic melanoma and potentially for other
CD133 expressing cancer types. In 2008, Rappa et al.
investigated the effects of CD133 down-regulation in
human metastatic melanoma, which result in slower cell
growth, reduced cell motility, decreased capacity to form
spheres under stem cell-like growth conditions and
reduced capacity of the cells to metastasize. Monoclonal
antibodies directed against two different epitopes of the
CD133 protein induced a specific, dose-dependent cyto-
toxic effect. In cells with only residual CD133 expression,
microarray analysis revealed expression changes for 143
annotated genes. 13% of the up-regulated genes coded for
Wnt inhibitors [32]. In it's normal function Wnt signaling
is crucial for tissue homeostasis and self-renewal in a
variety of adult tissues as well as embryonic development
and hematopoesis [33,34]. Additionally Wnt has been
implicated as being one of the drivers of oncogenesis in
various organs [35-37].
However, previous experiments revealed that some
tumor cells, which do not express CD133, are also capa-
ble of self-renewal and are tumorigenic. For human
gliomas Wang et al. demonstrated that CD133-  cells
derived from 6 different patients were tumorigenic when
implanted into brains of nude rats. For 3 of these patients,
analysis showed that the resulting tumors contained
CD133 positive cells [38].
Even more contradictory are the results in C6 glioma
cells: Whereas Zhou et al. demonstrated that this cell line
contains only a small fraction of cells that can form tumor
spheres in serum-free stem cell medium and express stem
cell markers CD133 and NESTIN [39], Zheng et al. con-
c l u d e d  t h a t  t h e  C 6  l i n e  i s  m a i n l y  c o m p o s e d  o f  C S C s ,
although many of them are CD133- [40]. Each of the
tested single C6 cells was able to generate a clone and
subclones in serum-containing medium, which subse-
quently gave rise to a xenograft glioma in nude mice. The
latter group confirmed these results the following year
showing that most C6 cells are cancer stem-like cells with
characteristics of self-renewal, multilineage differentia-
tion potentials in vitro, and tumorigenic capacity in vivo
irrespective of their CD133 expression [41].
CD133+  and CD133-  cells of lung cancer were also
examined for their abilities of colony formation, self-
renewal, proliferation, differentiation and invasion, as
well as resistance to chemotherapeutic drugs. The results
suggested that both the CD133+ and CD133- subpopula-
tions contain similar numbers of cancer stem cells since
they displayed similar abilities [42]. Analogical results
were obtained for human metastatic colon cancer cells
[43].
Despite the fact that not all groups concurrently used
the AC133 antibody to isolate CD133+ cells, the choice of
antibody would explain these contradictory findings only
to some extent. Even research groups that investigated
the same cell type with the same type of antibodies
arrived at different conclusions regarding the use of
CD133/AC133 as CSC marker [39,41]. Taken together,Welte et al. Cell Communication and Signaling 2010, 8:6
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CD133/AC133 is an indicator, but definitely not a reliable
marker for defining a population of CSCs in solid tumors
since it does not characterize tumor-initiating cells exclu-
sively. Therefore CD133/AC133 should be seen as a nec-
essary however insufficient criterion to identify CSCs in
solid tumors.
Comparably controversial results as for CD133 were
obtained from the investigations of various ATP-Binding
Cassette (ABC) transporters. Schatton et al. described
tumor-initiating cells capable of self-renewal and differ-
entiation in human melanoma defined by expression of
the chemoresistance mediator ABCB5. ABCB5 expres-
sion in tumor cells correlates with clinical melanoma pro-
gression. In serial xenotransplantation experiments
ABCB5+ melanoma cells were more tumorigenic than
ABCB5- cells. Additionally, ABCB5- cells showed no dif-
fer entia tion ca pacity since t hey e x clusive ly ga ve rise t o
ABCB5-  cells whereas ABCB5+  cells regenerated both
subpopulations. Using a monoclonal anti-ABCB5 anti-
body in nude mice, initial tumor growth as well as growth
of established tumors was inhibited by antibody-depen-
dent cell-mediated cytotoxicity in ABCB5+  cells [44].
Monzani et al. identified a subpopulation of human mela-
noma cells co-expressing ABCB1, ABCB5 and ABCC2 in
addition to stem cell markers which demonstrated higher
clonogenicity, self-renewal capacity and anchorage-inde-
pendent growth than the negative fraction [45]. Further-
more, they identified tumor-initiating cells in human
melanoma by the expression of ABCG2 which is coex-
pressed with CD133 [7]. For colon, breast and prostate
cancer cell lines however, these results could not be con-
firmed [46]. Patrawala et al. compared ABCG2+  and
ABCG2- cancer cells with respect to their tumorigenicity
in vivo, but no significant difference in tumor incidence
or latency periods comparing the two populations was
observed [46]. Finally, Quintana et al. examined the
expression of more than 50 surface markers on mela-
noma cells and injected these cells into NOD/SCID mice
lacking the interleukin-2 gamma receptor. In every case,
tumors arose from all fractions of cells. No known marker
distinguished tumorigenic from non-tumorigenic cells
[12].
Concluding these results, it seems as if tumor-initiating
cells are phenotypically heterogeneous and no marker or
set of markers has been found to identify CSCs in solid
tumors in general nor for specific tumor entities.
Dye exclusion assays
In contrast to preferably cell-type specific surface mark-
ers, the use of Hoechst-dye to identify and isolate CSCs as
a so called side population (SP) overcomes the barrier of
phenotypical markers and replaces it by more direct
functional markers [47]. The blue fluorescent Hoechst
33342 is a cell permeable bisbenzimidazole derivative
that binds to the minor groove of DNA. After excitation
of Hoechst its emission can be measured simultaneously
in the blue and red spectrum. But although Hoechst
enters viable cells, it is also actively pumped out by ATP-
Binding Cassette (ABC) transporters of the cell mem-
brane [48-50]. Goodell et al. were the first to identify that
hematopoietic stem cells are particularly effective at
pumping out Hoechst [51] since they express high levels
of ABC transporters resulting in a small side population
of weakly stained cells which can be observed during flow
cytometric analysis. To determine the size of the side
population, verapamil, an L-type calcium channel block-
ing agent serves as an important control. Blocking the
calcium channels inhibits the efflux of Hoechst-dye from
these cells, so it is then possible to gate for the side-popu-
lation, which is suspected to consist of cancer stem cells.
Subsequently, side populations were identified in various
established cell lines from breast cancer, lung cancer and
glioblastoma, suggesting that this phenotype defines a
class of cancer stem cells with inherently high resistance
to chemotherapeutic agents due to rapid efflux of those
compounds [52]. Kondo et al. were the first to come up
with the hypothesis that the side population resembles
the source of CSCs in C6 glioma cells since only SP cells
initiated tumors in multiple tissues in nude mice [53].
Also, purified side population cells from breast cancer
and thyroid cell lines showed higher tumorigenicity than
corresponding non-side population cells. They have a dif-
ferential gene expression profile and preferentially
express genes related to stemness, including NOTCH1
and  CTNNB1  at higher levels [46,54]. Grichnik et al.
identified side population cells in metastatic melanoma
cell lines which, compared to non-side population cells
were small in size, less melanized, had a decreased prolif-
eration rate and gave rise to a heterogeneous cell popula-
tion [55]. All these findings support the isolation of side
populations via Hoechst staining as an identification
method for CSCs. Additionally, this method could help to
identify more specific molecular CSC markers by com-
paring the expression profiles of SP and non-SP cells
which is crucial for the establishment of targeted cancer
therapies.
The main criterion of CSCs in contrast to non-CSCs is
their unique capability to differentiate and recapitulate all
cell types within a tumor. The results of several groups
led to the conclusion that the analysis of a SP via Hoechst
staining is a useful technique to isolate putative CSCs.
They demonstrated that only SP cells generate both SP
and non-SP cells in cell culture while non-SP cells fail to
do so [52,53,56,57]. Furthermore, they were able to initi-
ate tumors in xenograft transplantation experiments with
very low numbers of SP cells, whereas non-SP cells were
either not at all tumorigenic or only upon injection of
multifold more cells compared to the SP.Welte et al. Cell Communication and Signaling 2010, 8:6
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In contrast to these encouraging findings, results from
studies with thyroid, gastrointestinal, adrenocortical and
glioma cancer cells question the possibility to identify
CSCs by their efflux-capacity. They depict very well that
non-SP cells are able to generate SP cells, have similar
growth rates and tumor-initiating capacity as SP cells
[54,58-60].
The same controversial results were obtained regarding
the expression of specific stem cell/CSC markers on SP
cells. Although it was previously shown that intestinal
epithelial stem cells can be isolated as a side population
(SP) by FACS after staining with Hoechst [61] this con-
cept did not apply to gastrointestinal cancer cells tested
by Burkert et al. [58]. SP cells of several gastrointestinal
cancer cell lines showed no increased expression of stem
cell markers like CD133, CD44, Musashi-1, Oct-4 and
CD117 compared to non-SP cells. Both fractions were
similarly clonogenic in vitro, tumorigenic in vivo, and dis-
played similar differentiation potential in vitro and  in
vivo.
ABC transporters that most notably account for the
efflux of Hoechst are ABCG2 (Bcrp1) and Mdr-1 (also
known as P-glycoprotein or ABCB1) [48,50,51,62,63].
This is concordant with the findings that these genes are
highly expressed on SP cells but not on non-SP cells
[46,52]. Congruously, putative CSCs in the SP have
greater capacity to expel cytotoxic drugs used in cancer
therapy, therefore improve their survival and finally reca-
pitulate the whole tumorigenesis resulting in a relapse
after what seems like a successful cancer treatment
[52,64].
However, expression levels of ABCG2 and Mdr-1 was
shown to be identical on non-SP and SP cells in gastroin-
testinal cancer indicating that there may be additional
factors responsible for the Hoechst effluxing property
[58]. Furthermore, other studies showed that side popula-
tion cells obviously express some transporter molecules
responsible for Hoechst efflux. But this alone seems to be
insufficient to ensure chemotherapy resistance associated
with a survival benefit over non-SP cells [59].
A good example of the influence of technical factors on
the results is the comparison of studies from Kondo et al.
and Patrawala et al. Both groups studied the same cell
lines, but the yield of SP cells varied among the magni-
tude of 10 [46,53].
Due to these controversial findings some scientists
argue that Hoechst staining and isolation of SP cells can-
not be applied to identify and isolate CSCs, at least for
some tumor entities.
We think these controversial results are mostly due to
inefficient and lenient sorting procedures that never
result in 100% pure CSC and non-CSC fractions. Varia-
tions in the staining protocol and FACS procedure can
have enormous influence on the yield, viability and
homogeneity of side population cells, affecting all later
analyses done with these cells. In order to gain reproduc-
ible results, tissue dissociation to single cell suspension
levels and cell counting need to be optimized. Optimal
Hoechst concentration should be independently deter-
mined for each new tissue studied and the optimal
Hoechst concentration should be within the plateau
region [65]. But Hoechst concentration is exactly the
parameter that mostly differs among published data.
Used concentrations ranged from 2-10 μg/ml and the
incubation time from 30-120 minutes [53,55,66-71].
Furthermore, it has been shown that various cell types
are unequally sensitive to verapamil which serves as an
important control. Nethertheless, most groups apply a
concentration of 50 μM verapamil without determining
the cell-line specific sensitivity prior to the SP sorting
[46,55,67].
The reasons to explain the differences between Kondo
et al. and Patrawala et al. range from the use of different
flow cytometers and modified protocols [46]. Indeed,
Patrawala's group used higher Hoechst concentrations
than Kondo and according to studies from Kunkel higher
Hoechst concentrations result in a smaller SP [53].
Patrawala et al. therefore legitimately reasoned that their
experimental setup was more stringent for the identifica-
tion of putative CSCs [46].
In addition to the technical aspects of FACS sorting, it
was demonstrated that the SP size depends on the density
of cells in culture. SP cells preferentially survive at very
low plating density, because such clonal growth favors the
presence of CSCs [54].
Due to the range of parameters that can dramatically
influence SP analyses, results from such sorting experi-
ments should be compared very critically. Optimized and
standardized protocols for each cell type as well as strin-
gent cell culture and isolation settings are required to
eliminate the risk of analyzing different SP cells. These
standards will help to abolish skepticism and uncertainty
about the general validity of the technique and potential
of SP cells.
Ultimately, the toxicity of Hoechst should be addressed
and always kept in mind when applying this dye to isolate
putative CSCs. As Hoechst binds to DNA, it can disrupt
DNA replication during cell division. Consequently, it is
potentially mutagenic and carcinogenic. What causes the
researcher to adhere to strict safety regulations while
working with Hoechst, also affects all cells that are
stained in vitro. Already in 1986, Siemann et al. evaluated
the toxicity of this stain in cells derived from sarcomas.
Hoechst toxicity increased with increasing exposure
times resulting in 25- to 45-fold reduced survival in irra-
diated cells and 4- to 5-fold reduced survival in untreated
cells. Furthermore, cytotoxic effects of Hoechst 33342
were found to be significantly greater in cells in the SWelte et al. Cell Communication and Signaling 2010, 8:6
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phase than in cells in G1 and G2-M phases of the cell
cycle [72]. Recently, these results were confirmed by Shen
et al. They showed that Hoechst staining leads to obvious
morphological alterations and increased apoptosis in the
C6 glioma cell line [41]. This toxicity, particularly its cell
cycle specificity, suggests a potentially severe limitation
for the use of Hoechst dye in combination with fluores-
cence activated cell sorting. Non-SP cells with lower
capacity to efflux this dye will suffer more from its effects
compared to putative CSCs of the SP. Hence, Wu et al.
argued that SP cells may not represent stem-like cells, but
r a t h e r ,  a  p o p u l a t i o n  o f  c e l l s  t h a t  i s  a b l e  t o  e s c a p e  t h e
lethal effects of Hoechst staining [73].
An alternative to the use of Hoechst provides the use of
Rhodamine 123 which was shown to be non-toxic to cells
even at high concentrations [74]. The cell-permeable,
green-fluorescent Rhodamine 123 binds to mitochon-
drion membranes. Like Hoechst it is actively pumped out
of the cells by ABC transporters, e.g. MDR1 and ABCB1
[75,76]. Liu et al. compared the use of Rhodamine 123
and Hoechst to isolate CSCs in a hepatocellular cell line.
The percentages of SP and non-SP after staining with
Rhodamine 123 or Hoechst were the same as well as the
proliferative abilities in vitro,  e x p r e s s i o n  o f  s t e m  c e l l
markers and tumorigenicities in vivo of both obtained
side populations [77]. Taken together, use of Rhodamine
123 in combination with flow cytometric cell sorting may
be a useful method for CSC identification.
In vivo transplantation experiments - are CSCs rare cells?
Until today the gold standard in validating a putative CSC
fraction is their transplantation into immunodeficient
mice. If CSCs are really enriched in this population, these
cells should have a several fold higher capacity to form
tumors compared to the control fraction where the cells
lack this CSC marker or the typical characteristics as
rapid efflux of Hoechst due to high expression of ABC
transporters.
In this manner, the side population after Hoechst stain-
ing and flow cytometric analysis was proved to be
enriched of tumor-initiating cells in thyroid [54], ovarian
[78] and breast cancer [46], glioma [46,53], melanoma
[70] and hepatocellular carcinoma [79]. Further on, xeno-
transplantation experiments validated certain CSC mark-
ers like ABCB5 for melanoma [44], CD133 for melanoma
[7], lung [19] and colon cancer [18,80] and CD20 for mel-
anoma [81].
Until two years ago, it seemed that only few cells iso-
lated from a tumor have the ability to initiate tumor
growth in transplantation experiments. But in 2008
Quintana et al. put this dogma of rare CSCs at least for
melanoma into question. They found out that melanoma-
initiating cells are only rare in NOD/SCID mice if moni-
toring tumor formation for a short term, like most
researcher do, and using the common assays described in
literature.
But this frequency could be significantly increased by
following melanoma formation for more than 8 weeks,
using NOD/SCID IL2Rγnull mice that lack natural killer
cell activity compared to NOD/SCID mice and injecting
melanoma cells together with Matrigel, a mixture of
structural proteins and growth factors. Overall, after
injection of single, unselected melanoma cells, 27% initi-
ated a tumor suggesting that so far the frequency of mela-
noma-initiating cells was significantly underestimated
[12].
With this modified assay Quintana et al. provided a
good example of the importance of interactions between
tumor cells and their extracellular matrix and how they
dictate whether or not a tumor develops from a mutated
cell.
Matrigel represents a rich store of matrix proteins as
well as angiogenic and growth factors which promote
tumor growth and metastasis [82]. But still the aberrant
extracellular matrix of immunodeficient mice cannot
substitute for all factors of the human microenvironment,
and the stem cell niche which is crucial to initiate tumor
growth is not reconstituted in xenotransplantation mod-
els [83].
This is supported by studies that show that the fre-
quency of cells that sustain tumor growth was dramati-
cally increased using allograft transplantation models.
Kelly et al. transferred mouse lymphoma cells into non-
irradiated histocompatible recipient mice. Regardless of
cell number injected, all animals developed a tumor even
when transplanting only a single neoplastic cell [84].
Additionally, studies using spontaneously arising tumors
in syngeneic rodents have shown that the number of cells
required to transplant a tumor depends on the site of
transplantation and the type of cells [85].
Last but not least, the amount of tumor-initiating cells
is influenced by the experimental setup. Enzyme treat-
ment during the preparation of the cell suspensions and
sorting procedure might decrease the viability of tumor
cells and modify protein expression, thereby affecting the
population into which the cells are sorted and the ability
of these proteins to play a role in tumor formation follow-
ing transplantation [86].
But instead of focusing on the establishment of meth-
ods to increase the percentage of tumor-initiating cells in
artificial xenograft transplantation models with immuno-
suppressed mice, should we not answer the question
which cells initiate tumors in healthy organisms with
intact immune systems as well as resist cancer therapies
and causing relapses, respectively? In 2009 Schatton and
Frank proposed that CSCs in human melanoma that
express the chemoresistance mediator ABCB5 might be
responsible for melanoma immune evasion [87]. Thus,Welte et al. Cell Communication and Signaling 2010, 8:6
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immunomodulation might represent the key mechanism
by which CSCs promote tumorigenic growth.
Cancer stem cells, quo vadis?
Models serve the purpose of simplifying complex con-
texts. Traditionally, signaling cascades are depicted as
straight forward processes in a highly ordered manner.
This way of looking at biological systems started a true
gold rush in the field of stem cell marker identification.
So, in the past much effort was made to identify novel key
cancer stem cell markers for specific tumor entities, if not
a universal marker or set of markers for CSCs in all can-
cers. But in reality the biology with all its feedback loops,
branching, positive and negative modulators is much
more complex. This makes it a challenge to identify the
right components that uniquely define cancer stem cells.
On the other hand standards are needed to help inter-
preting the results of various groups working on the elu-
cidation of CSC nature. But into which direction should it
be leading to? Which methods, which protocols are going
to be the right ones?
One approach for the characterization of CSCs that was
not considered yet, could be the analysis of analogies
between cancer stem cells and induced pluripotent stem
(iPS) cells.
In 2006 Takahashi and Yamanaka were the first who
successfully reversed differentiated mouse embryonic or
adult fibroblasts into pluripotent stem cells by introduc-
ing only the four factors Oct3/4, Sox2, c-Myc and Klf4
and named these reprogrammed cells which exhibit the
morphology and growth properties of embryonic stem
(ES) cells and express ES cell marker genes, induced
pluripotent stem cells [88].
After inducing somatic cells with these four "Yamanaka
factors", Mikkelsen and colleagues found out that about
20% of the cells stained positive for the stem-cell marker
SSEA1, but only about 1.2% were fully reprogrammed.
Whereas fully reprogrammed cells showed gene expres-
sion and epigenetic states similar to that of ES cells, gene
expression profiling revealed that partially repro-
grammed cells re-activated only a small group of genes
related to stem cell renewal and maintenance, but yet
these cells are not pluripotent. Instead they exhibit a
down-regulation of structural genes and regulatory fac-
tors expressed in differentiated cells and up-regulation of
some lineage-specific and proliferative genes not
expressed in iPS cells [89].
Potentially, the same is true for cancer stem cells. Prob-
ably they represent an intermediate state between stem
cells and differentiated cells like partially reprogrammed
cells do between iPS cells and differentiated cells (Figure
2). Mikkelsen et al. showed that these differences are due
to epigenetic events like persistent DNA hypermethyla-
tion at pluripotency- and germ-cell-specific loci [89].
In addition, it is known that small molecules like the
histone deacetylase inhibitor valproic acid, the DNA
methyltransferase inhibitor 5-aza-cytidine or the kinase
inhibitor Kenpaullone facilitate iPS cell formation by
modeling epigenetic information [90-92].
The comparison of melanoma cells enriched for cancer
stem cells and non-cancer stem cells in our lab also
argues in favor of epigenetic regulation and maintenance
of the phenotype or alternative splicing since we found no
differences in coding mutations at the genome or tran-
scriptome level but tremendous varieties among gene
expression patterns (unpublished data).
T h i s  i s  a l s o  c o n s i s t e n t  w i t h  t h e  p l a s t i c i t y  o f  c a n c e r
because only epigenetic modulations can efficiently be
activated and reverted in short intervals. This model has
been recently discussed by Gupta et al. They postulated
that there might exist a dynamic equilibrium between
CSCs and non-CSCs within tumors that may be shifted in
one direction or another by contextual signals within the
tumor microenvironment that influence the probability
of interconversion between the CSC and non-CSC com-
partments [93]. This would also explain the varying
amounts of cancer stem cells within the same tumor
entity described by different groups.
Evidence for a conversion of CSC into non-CSCs and
vice versa were given by Platet et al. and Lichtenauer et al.
Both groups found that non-SP cells in flow cytometric
analyses after Hoechst staining are able to generate SP
cells [59,60]. That means bulk tumor cells can convert
into CSCs and explains the maintenance of the SP pheno-
type in long-term cell cultures. This dynamic equilibrium
Figure 2 Relationship between stem cell species. Stem cells are 
characterized by their ability to form many different types of tissues 
and their capacity to self-renew. With increasing level of differentiation 
from progenitor cell to differentiated cell, the plasticity reduces as does 
the proliferative capacity. Cancer stem cells form at the interface be-
tween stem cell and progenitor cells. This phenomenon has lately also 
been credited to iPS cells and their partially reprogrammed precursors.Welte et al. Cell Communication and Signaling 2010, 8:6
http://www.biosignaling.com/content/8/1/6
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was also seen within the partially reprogrammed cells in
the group of Jaenisch where cells positive for SSEA1 as
well as cells negative for this stem cell marker reverted to
the heterogeneous state within 1-2 passages in cell cul-
ture [89].
But still one question remains unsolved. How is this
equilibrium driven and which cells transmit the required
signals? Are the non-CSC alone really able to de-differen-
tiate into CSC or do they obtain the priming signals to
reconstitute the balance within the tumor microenviron-
ment from the small part of CSCs. MicroRNAs probably
play a role in facilitating the equilibrium of CSCs and
non-CSCs like they promote iPS cell formation by their
regulatory effects on epigenetic and transcriptional mod-
ulation [94]. We should learn from this quite new but
extensively investigated research field and try consigning
these new insights to the CSC research.
One - of course provocative - interpretation of the
seemingly contradictive findings on CSCs is that cancer
stem cells are neither a defined nor a definable sub-popu-
lation of cells within the tumor, but rather a highly
dynamic state in which only few cells at a time are in. We
learn from Heisenberg's "uncertainty principle" that in a
single experiment only the position (= state) or speed (=
change over time) can be determined with any given pre-
cision. This principle does not only hold true for quan-
tum mechanics, but also applies to observation made on
living cells. For example by sorting the cells for their stem
cell-like properties, the result is only a snapshot of the
cells' state, but we cannot deduce from this observation
that also the bulk cells cannot acquire such properties.
On the other hand, if we follow the dynamic changes in
the level of markers, we cannot determine whether this
comes from an increase in cells expressing the marker, or
if the expression level per cell has increased. Keeping this
in mind one has to be very careful when interpreting the
current literature on cancer stem cells.
Conclusions
Since Nixon's war on cancer billions of dollars were
invested in cancer research. But still, our understanding
of the biology of cancer does not help to cure this dread-
ful disease. The concept of cancer stem cells was very
welcome because it opened new perspectives in under-
standing and ultimately healing this disease.
Although it is tempting to explain tumor formation and
metastasis by the presence of stem cells, after almost a
decade of intense research, it seems that cancer stem cells
still do not explain how neoplasias evolve. The inconsis-
tencies in the experiments call for a more in depth analy-
sis of the cellular and signaling features of those cells. The
research therefore must focus on two things: (a) the
establishment of robust and reliable criteria to identify
and isolate cancer stem cells and (b) in parallel research-
ers must find and agree on an unbiased definition of what
a cancer stem cell really is. This may be the activation/
deactivation of specific pathways or the presence/absence
of expression of proteins that discriminate them from
other cells within the tumor.
In the worst case, many of the observations made in
cancer stem cells would be nothing but artefacts, which
are induced by the researcher by the artificial environ-
ment that is presented to the cells in form of the condi-
tions under which the cells are cultured. But even then,
the existence of subpopulations of cells with unique fea-
tures helped to make researchers more sensitive towards
the heterogeneity not only within a tumor in vivo, but
also in cell culture models in vitro.
From what we know about cancer stem cells today, we
would not expect the worst case to become true. It seems
more and more likely that this population of cells is not a
defined group of cells resting in a niche and populating
the tumor with amplifying cells, but that few or maybe
even many cells within the tumor can function as cancer
stem cells if induced, but also can go back to the state of a
" n o r m a l "  c a n c e r  c e l l .  O f  c o u r s e  t h i s  s c e n a r i o  m a k e s  i t
even more difficult to target these cells for therapeutic
reasons. Although, research has shed some light on the
matter, the question still remains unanswered: Are CSCs
in solid tumors elusive, or illusive?
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